losartan has been researched along with Contusions in 4 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Contusions: Injuries resulting in hemorrhage, usually manifested in the skin.
| Excerpt | Relevance | Reference |
|---|---|---|
| "When compared with MDSC transplantation alone, MDSC/losartan treatment resulted in significantly decreased scar formation, an increase in the number of regenerating myofibers, and improved functional recovery after muscle contusions." | 3.83 | The Combined Use of Losartan and Muscle-Derived Stem Cells Significantly Improves the Functional Recovery of Muscle in a Young Mouse Model of Contusion Injuries. ( Fu, FH; Huard, J; Kawakami, Y; Kobayashi, M; Ota, S; Otsuka, T; Terada, S, 2016) |
| "Muscle contusions are a common type of muscle injury and are frequently encountered in athletes and military personnel." | 1.39 | Use of an antifibrotic agent improves the effect of platelet-rich plasma on muscle healing after injury. ( Fu, FH; Huard, J; Kobayashi, M; Kobayashi, T; Mifune, Y; Ota, S; Otsuka, T; Oyster, N; Takayama, K; Terada, S; Vadalà, G; Witt, M, 2013) |
| "Losartan (Los) is a Food and Drug Administration-approved antihypertensive medication that has a well-tolerated side effect profile." | 1.39 | The timing of administration of a clinically relevant dose of losartan influences the healing process after contusion induced muscle injury. ( Ambrosio, F; Cummins, JH; Fu, FH; Huard, J; Kobayashi, T; Ota, S; Terada, S; Tobita, K; Uehara, K, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Terada, S | 3 |
| Ota, S | 3 |
| Kobayashi, M | 2 |
| Kobayashi, T | 2 |
| Mifune, Y | 1 |
| Takayama, K | 1 |
| Witt, M | 1 |
| Vadalà, G | 1 |
| Oyster, N | 1 |
| Otsuka, T | 2 |
| Fu, FH | 3 |
| Huard, J | 3 |
| Evans, CH | 1 |
| Kawakami, Y | 1 |
| Uehara, K | 1 |
| Tobita, K | 1 |
| Ambrosio, F | 1 |
| Cummins, JH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot Study of Losartan to Reduce Radiation Induced Fibrosis in Breast Cancer Patients[NCT05637216] | Phase 2 | 40 participants (Anticipated) | Interventional | 2023-08-17 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 other studies available for losartan and Contusions
| Article | Year |
|---|---|
Use of an antifibrotic agent improves the effect of platelet-rich plasma on muscle healing after injury.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Contusions; Enzyme-Linked Immunosorbent Assay; Fem | 2013 |
Platelet-rich plasma à la carte: commentary on an article by Satoshi Terada, MD, et al.: "use of an antifibrotic agent improves the effect of platelet-rich plasma on muscle healing after injury".
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Contusions; Female; Losartan; Muscle, Skeletal; Pl | 2013 |
The Combined Use of Losartan and Muscle-Derived Stem Cells Significantly Improves the Functional Recovery of Muscle in a Young Mouse Model of Contusion Injuries.
Topics: Animals; Cicatrix; Contusions; Disease Models, Animal; Losartan; Mice; Muscle, Skeletal; Myogenic Re | 2016 |
The timing of administration of a clinically relevant dose of losartan influences the healing process after contusion induced muscle injury.
Topics: Animals; Antihypertensive Agents; Cell Line; Contusions; Dose-Response Relationship, Drug; Follistat | 2013 |